Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC33999 | PMC |
| http://dx.doi.org/10.1073/pnas.97.14.7673 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Xanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFPartial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.
Curr Neuropharmacol
January 2025
Clinic Villa Von Siebenthal, Rome, Italy.
Introduction/objective: Schizophrenia with substance use disorder is a complex clinical condition that may increase treatment resistance. Cannabis use disorder is frequently associated with psychosis and the causal link has still to be defined. Partial D2/3 agonists may ensure limbic dopamine release normalization while avoiding reduced frontocortical dopamine release, which would contribute to negative symptoms.
View Article and Find Full Text PDFNovel Electrochemiluminescence Sensor for Dopamine Detection Based on Perylene Diimide/CuO Nanomaterials.
Molecules
January 2025
School of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng 252059, China.
Dopamine (DA) is an important catecholamine neurotransmitter and its abnormal concentration is closely related to diseases such as hypertension, Parkinson's disease and schizophrenia. Due to the advantages of high sensitivity and fast response for electrochemiluminescence (ECL), developing ECL sensors for detecting DA was very critical in clinical diagnosis. ECL resonance energy transfer (ECL-RET) was an effective signaling mechanism.
View Article and Find Full Text PDFOlanzapine exposure disordered lipid metabolism, gut microbiota and behavior in zebrafish (Danio rerio).
Comp Biochem Physiol C Toxicol Pharmacol
January 2025
College of Fisheries, Henan Normal University, Xinxiang 453007, PR China; Engineering Technology Research Center of Henan Province for Aquatic Animal Cultivation, Henan Normal University, Xinxiang 453007, PR China. Electronic address:
Olanzapine (OLZ) is widely used in the treatment of schizophrenia, and its metabolic side effects have garnered significant attention in recent years. Despite this, the specific side effects of OLZ and the underlying mechanisms remain inadequately understood. To address this gap, zebrafish (Danio rerio) were exposed to OLZ at concentrations of 35.
View Article and Find Full Text PDFPopulation pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia.
Drug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!